Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment
of Focal Segmental Glomerulosclerosis (FSGS)
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Seeking Alpha / 1 hour ago 2 Views
Comments